Jiaheng Wang, Linjuan Xu, Gang Wang, Wenping Wu, Hongwei Kong
{"title":"ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming","authors":"Jiaheng Wang, Linjuan Xu, Gang Wang, Wenping Wu, Hongwei Kong","doi":"10.1016/j.exphem.2025.104862","DOIUrl":null,"url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a complex hematologic malignancy characterized by rapid progression and high relapse rates. Zinc finger CCCH domain-containing protein 13 (ZC3H13) has been implicated in the pathogenesis of various diseases, but its role in AML remains unclear. This study aimed to elucidate the function and underlying mechanisms of ZC3H13 in AML. Gene expression patterns and correlations with patient survival were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. ZC3H13 expression was quantified in AML bone marrow samples and cell lines via real-time reverse-transcription PCR (qRT-PCR) and Western blotting. Cell proliferation was assessed using Cell counting kit-8 (CCK-8) and 5-ethynyl-2′-deoxyuridine (EdU) assays, whereas flow cytometry was employed to evaluate cell cycle progression, apoptosis, and reactive oxygen species (ROS) levels. Glycolytic activity—including glucose consumption, lactate production, and ATP levels—was measured using commercial kits. Oxidative stress markers such as superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH) were also quantified. The LinkedOmics database was used to identify ZC3H13-associated genes and predict their functional correlations. Potential m6A modification sites on FOXP1 mRNA were predicted using the SRAMP tool and validated through methylated RNA immunoprecipitation (MeRIP) assays. A dual-luciferase reporter assay confirmed direct binding of ZC3H13 to the FOXP1 promoter. ZC3H13 was found to be highly expressed in AML bone marrow and cell lines. Functionally, ZC3H13 promoted cell proliferation, enhanced glycolysis, and suppressed both apoptosis and oxidative stress. Mechanistically, ZC3H13 stabilized FOXP1 expression via m6A methylation, thereby contributing to AML progression. In conclusion, ZC3H13 accelerates AML development by modulating the m6A-FOXP1 axis, leading to metabolic reprogramming. These findings provide novel insights into AML pathogenesis and offer potential targets for therapeutic intervention.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104862"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301472X25001535","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute myeloid leukemia (AML) is a complex hematologic malignancy characterized by rapid progression and high relapse rates. Zinc finger CCCH domain-containing protein 13 (ZC3H13) has been implicated in the pathogenesis of various diseases, but its role in AML remains unclear. This study aimed to elucidate the function and underlying mechanisms of ZC3H13 in AML. Gene expression patterns and correlations with patient survival were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. ZC3H13 expression was quantified in AML bone marrow samples and cell lines via real-time reverse-transcription PCR (qRT-PCR) and Western blotting. Cell proliferation was assessed using Cell counting kit-8 (CCK-8) and 5-ethynyl-2′-deoxyuridine (EdU) assays, whereas flow cytometry was employed to evaluate cell cycle progression, apoptosis, and reactive oxygen species (ROS) levels. Glycolytic activity—including glucose consumption, lactate production, and ATP levels—was measured using commercial kits. Oxidative stress markers such as superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH) were also quantified. The LinkedOmics database was used to identify ZC3H13-associated genes and predict their functional correlations. Potential m6A modification sites on FOXP1 mRNA were predicted using the SRAMP tool and validated through methylated RNA immunoprecipitation (MeRIP) assays. A dual-luciferase reporter assay confirmed direct binding of ZC3H13 to the FOXP1 promoter. ZC3H13 was found to be highly expressed in AML bone marrow and cell lines. Functionally, ZC3H13 promoted cell proliferation, enhanced glycolysis, and suppressed both apoptosis and oxidative stress. Mechanistically, ZC3H13 stabilized FOXP1 expression via m6A methylation, thereby contributing to AML progression. In conclusion, ZC3H13 accelerates AML development by modulating the m6A-FOXP1 axis, leading to metabolic reprogramming. These findings provide novel insights into AML pathogenesis and offer potential targets for therapeutic intervention.
期刊介绍:
Experimental Hematology publishes new findings, methodologies, reviews and perspectives in all areas of hematology and immune cell formation on a monthly basis that may include Special Issues on particular topics of current interest. The overall goal is to report new insights into how normal blood cells are produced, how their production is normally regulated, mechanisms that contribute to hematological diseases and new approaches to their treatment. Specific topics may include relevant developmental and aging processes, stem cell biology, analyses of intrinsic and extrinsic regulatory mechanisms, in vitro behavior of primary cells, clonal tracking, molecular and omics analyses, metabolism, epigenetics, bioengineering approaches, studies in model organisms, novel clinical observations, transplantation biology and new therapeutic avenues.